[Penetration of levofloxacin in bile].
The penetration into bile of a new pyridonecarboxylic acid derivative, levofloxacin (LVFX), was studied in a closs-over method with ofloxacin (OFLX) as the control drug in 6 post-operative patients. The lengths of time to the maximum concentrations in bile and the total areas under the curves were both almost the same for these 2 compounds, although the maximum bile concentration of LVFX was slightly lower than that of OFLX. A stability test for LVFX in human bile revealed that over 95.4% of the initial amount was recovered up to 24 hours after commencement of incubation at a room temperature, thus the stability in bile was similar to that in water. The penetration of LVFX which possesses twice as strong antibacterial activities as OFLX was similar to that of OFLX, suggesting that LVFX is useful against bile duct infections.
Mizuno
A
A
Department of Surgery, Takahama Municipal Hospital.
Suzuki
T
T
Taniguchi
M
M
Yura
J
J
Shinagawa
N
N
Ishikawa
S
S
Mashita
K
K
Suzui
K
K
Ishikawa
M
M
Ishihara
H
H
D000368:Aged; D001646:Bile / Q000378:metabolism*; D002761:Cholangitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000493:pharmacokinetics* / Q000627:therapeutic use
D064704:Levofloxacin; D015242:Ofloxacin